ATG presents computational biology tools at MoDiPro workshop
Press Release | ATG:biosynthetics GmbH
APRIL 24, 2018
Merzhausen, Germany: – German-based contract research organization ATG:biosynthetics (ATG) will present it leading-edge computational biology tools at the upcoming workshop “Biotechnology Meets IT”.
The event is hosted by the ZIM Collaboration Network as part of the “Models for Diagnostics and Process Optimization” (MoDiPro) project of which ATG is a leading member.
Delegates will include biotechnology research professionals from industry and academia, seeking to optimize their processes through digitization or their collected data, e.g. for research & development, scale-up, production optimization or diagnostics.
Computational biology leaders
ATG: biosynthetics will be presenting its latest contributions in data acquisition & collection, data structuring & stratification and data reduction & integration.
“In all these fields, ATG is at the frontiers of computational biology in preclinical research and veterinary sciences,” said ATG’s CEO, Dr. Hubert S. Bernauer.
We will be showing how our use of molecular and serological experimental and clinical data sets can enable improved decision-making processes aiming on best candidates in terms of highest plausibility of target efficacy and less side effects of vaccines and drugs,” said Dr. Bernauer.
Developing diagnostic tools
The German-language workshop aims to build and strengthen contacts between biotechnology and the IT industry, focusing on starting points for projects concerned with optimization of biotechnological development and production processes for the development of prognosis tools for diagnostics. It will feature invited experts who will provide insights into the added value of data analysis methods and predictive computer models.
The workshop is staged as an all-day event on April 26, 2018, at 9:30 am at the Am Klopferspitz building in Martinsried, home of the Ellipse 1 Innovation and founding center for biotechnology. It is organized by Industrial Biotechnology Bayern Netzwerk GmbH, as network manager of the MoDiPro ZIM cooperation network.
About ATG: biosynthetics
Advanced Technical Genetomics (ATG) is a German-based company that specializes in synthetic biology, combinatorial gene design and multi-gene expression. Located in Merzhausen near Freiburg, ATG offers a complete range of multi-gene and multi-peptide expression products and services for synthetic and molecular biology as well as allied research and development areas.
ATG: biosynthetics possesses particular strengths in designing tailor-made solutions (e.g., gene cluster and complete pathway designs) that harness its technologies and services in related product areas that include gene synthesis, bioinformatics, molecular in silico biodesign, epitope mapping and pathway engineering. These provide clients with individual products and services or integrated solutions that offer a complete product & service package for peptide/gene expression and synthetic biology applications.
ATG seeks partnerships and outsourcing projects that aim at developing and marketing high-potential applications, e.g. creating high efficiency DNA- and protein-based vaccines.
The MoDiPro (“Models for diagnostics and process optimization”) initiative is an alliance of nine technologically advanced companies and organizations with different fields of expertise in applying advanced technologies, big data and computer-supported modeling to develop more individualized medicine.
The alliance aims to develop 21st century products such as diagnostic and decision-supporting digital tools for physicians or clever sensor-control-modules that optimize industrial production processes in real-time.
The strategic focus of the “MoDiPro” cooperation network is the digitization of biotechnology with the two main fields of application being Industrial Biotechnology, sustainable economy and individualized medical technology.
The network partners aim to harness methodologically advanced modeling and prognoses to make biotechnological processes more efficient and enable optimized and fast decisions in medicine. Products targeted are software solutions and hardware components as well as services based on the predictive power of computer models.
The network framework is provided by the Industrielle Biotechnologie Bayern Netzwerk GmbH (IBB Netzwerk GmbH), which is a network and service organization in the field of Industrial Biotechnology and sustainable economy. More information at: http://www.ibbnetzwerk-gmbh.com/en/service/pressebereich/.
Dr. Hubert S. Bernauer , CEO, ATG:biosynthetics GmbH
Tel: +49 (0)761 888 9424